Skip to content
    Clinical Trials

    Can disease be identified before symptoms begin? Mayo Clinic researchers are looking for answers

    MillikinMayo Clinic

    Can disease be identified before symptoms begin? Mayo Clinic researchers are looking for answers
    The biological processes underpinning major chronic illnesses—including Alzheimer disease, heart failure, malignancies, and chronic kidney disease—routinely develop silently over years or decades before clinical thresholds for diagnosis are reached. To bridge this window of undetected progression, Mayo Clinic has initiated the Precure Research program, an integrated effort aimed at characterizing the molecular and physiological transition from health to disease across the brain, heart, kidneys, liver, and lungs.
    The initiative integrates multi-omic data (genomics, proteomics, metabolomics, and immune profiling) with longitudinal electronic health records, wearable device biosignals, and exposome data, which captures lifetime environmental pollutants, lifestyle factors, and chemical exposures. High-throughput artificial intelligence is deployed across the Mayo Clinic Platform to identify subclinical patterns across cross-disease pathways, such as systemic inflammation, cellular aging, and metabolic dysfunction. Ongoing pilot assessments within this framework include evaluations of saliva-based biosensors for head and neck cancer triggers, the impact of long-term air pollution on solid-organ transplant outcomes, and the influence of xenobiotic chemical exposures on pharmacokinetics.
    Initial findings supporting this proactive paradigm demonstrate actionable clinical yield: in a large genetic investigation, researchers identified inherited predispositions for cardiovascular disease and cancer in nearly 2,000 participants who had no prior clinical indications of risk. By establishing when subclinical biological trajectories deviate toward pathology, the research aims to transition clinical management from reactive disease mitigation to predictive, early-stage intervention that preserves healthspan before irreversible tissue or organ damage occurs.

    Key Takeaways

    • Large-scale genomic screening identified previously unrecognized inherited risks for cardiovascular disease and cancer in nearly 2,000 asymptomatic individuals.
    • Biological and molecular markers of neurodegeneration and oncogenesis demonstrate measurable alterations years to decades prior to the manifestation of clinical symptoms.